Publication search
with Peginterferon α-2b as keyword
Miyase, Shiho Haraoka, Katsuki Ouchida, Yoshihiro Morishita, Yuko Fujiyama, Shigetoshi
Published in
Journal of Gastroenterology
BackgroundPegylated interferon (PegIFN) plus ribavirin is the standard therapy for patients with chronic hepatitis C genotype 1. Although several randomized clinical trials have compared PegIFNα-2a with PegIFNα-2b, these 2 regimens have not been directly compared in Asian patients. We, therefore, compared the safety and antiviral efficacy of these ...
Chen, Lei L. Chen, Xinjian Choi, Haesun Sang, Hongxun Chen, Leo C. Zhang, Hongbo Gouw, Launce Andtbacka, Robert H. Chan, Benjamin K. Rodesch, Christopher K.
...
Published in
Cancer Immunology, Immunotherapy
Cancer survivors often relapse due to evolving drug-resistant clones and repopulating tumor stem cells. Our preclinical study demonstrated that terminal cancer patient’s lymphocytes can be converted from tolerant bystanders in vivo into effective cytotoxic T-lymphocytes in vitro killing patient’s own tumor cells containing drug-resistant clones and...
Daud, A. I. Xu, C. Hwu, W.-J. Urbas, P. Andrews, S. Papadopoulos, N. E. Floren, L. C. Yver, A. DeConti, R. C. Sondak, V. K.
...
Published in
Cancer Chemotherapy and Pharmacology
PurposeHigh-dose pegylated interferon α-2b (peginterferon α-2b) significantly decreased disease recurrence in patients with resected stage III melanoma in a clinical study. We investigated the pharmacokinetics (PK) and safety of high-dose peginterferon α-2b in patients with high-risk melanoma.MethodsFor PK analysis, 32 patients received peginterfer...
